Paul Corn is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 789 publications with 14,799 citations (h-index 55); ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304000
Telephone
713-792-6161Provider last certified this registry record 19 Nov 2025.
Clinical trials
- Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
Sponsor: M.D. Anderson Cancer Center
- Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
Sponsor: M.D. Anderson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year202526 payments
- Janssen Scientific Affairs, LLCProgram year20251 payment
- Sumitomo Pharma America, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
38.9%Cytochrome P450 17A1 Inhibitor12.3%Abiraterone Acetate100%Part D≥33 patientsAndrogen Receptor Inhibitor8.6%Xtandi68%Bicalutamide32%Part D<11 patients+ 5 more classes in this area
Nervous system
26.6%Opioid Agonist14.4%Morphine Sulfate Er41%Morphine Sulfate27%Oxycodone Hcl23%Oxycontin9%Part D<11 patientsCentral Nervous System Stimulant5%Methylphenidate Hcl100%Part D≥14 patients+ 3 more classes in this area
Metabolism & gastrointestinal
15.9%Corticosteroid12.8%Prednisone100%Part D≥36 patientsSerotonin-3 Receptor Antagonist3%Ondansetron Odt100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2004–2007 per NIH RePORTER. The latest:
- Regulation of the von Hippel-Lindau Protein
University of Tx Md Anderson Can Ctr
FY2007$127,710K08CA093425 - Regulation of the von Hippel-Lindau Protein
University of Tx Md Anderson Can Ctr
FY2006$127,710K08CA093425 - Regulation of the von Hippel-Lindau Protein
University of Texas Md Anderson Can Ctr
FY2005$127,710K08CA093425
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy
Science Translational Medicine
2022 - ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer
Clinical Cancer Research
2021 - Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer
Science Translational Medicine
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”